SOPHiA GENETICS technology will help increase
cancer research abilities
BOSTON and LAUSANNE, Switzerland, May 16, 2023
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company in the healthcare space and a leader in
data-driven medicine, today announced that Natural State
Laboratories, a xfull-service, state-of-the-art molecular
laboratory based in Little Rock,
Arkansas, has chosen SOPHiA GENETICS technology to help them
expand their cancer testing and research capabilities. Natural
State Laboratories will soon begin using SOPHiA DDM™ to launch
in-house testing for hereditary cancers.
The SOPHiA DDM™ technology will streamline and expedite analysis
and interpretation workflows for Natural State Laboratories,
increasing the volume of genomic profiles analyzed. With the
in-house analysis and increased testing speed, Natural State
Laboratories will be able to serve a much wider population in the
region.
"At Natural State Laboratories, we believe that the future of
cancer is in how quickly we are aware of the presence of and
precursors to cancer," said Ruslana
Tytarenko, MS, BSc, MLS (ASCP)CM, Lab Technical Supervisor.
"The SOPHiA DDM™ Platform will increase the volume of research and
testing we're able to conduct, helping to more quickly analyze more
genomic profiles and identify those who are pre-dispositioned to
hereditary cancers."
Hereditary cancer is responsible for roughly 10 percent of all
diagnosed cancers1. The ability to identify a
pre-disposition to hereditary cancers can help clinical researchers
with the formulation of future treatment plans. And, while testing
is somewhat simple via next-generation sequencing (NGS), which is
prevalent in the detection of biomarkers for hereditary cancers,
the amount of data resulting from NGS is vast and complex.
The SOPHiA DDM™ Platform uses artificial intelligence and machine
learning with patented technologies to analyze raw NGS data,
streamlining it for simplified interpretation, and expedited
reporting.
"The development of Natural State Laboratories' new hereditary
cancer test, using the SOPHiA DDM™ technology, will continue
furthering our work to democratize data-driven medicine," said
Ken Freedman, Chief Revenue Officer,
SOPHiA GENETICS. "With this new
test, Natural State Laboratories will have an in-house database
that allows them to increase efficiency and better serve a wider
population. We're excited to be part of their next step in cancer
testing and research for the surrounding population."
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1 Al Harthi, F. S., et al. (2020) 'Familial/inherited
cancer syndrome: a focus on the highly consanguineous Arab
population', npj Genomic Medicine, 5, 3
View original content to download
multimedia:https://www.prnewswire.com/news-releases/natural-state-laboratories-chooses-sophia-genetics-to-help-launch-their-in-house-hereditary-cancer-testing-301825375.html
SOURCE SOPHiA GENETICS